Novel Anti-Aging Benzoquinone Derivatives from

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. In silico screening, ADMET analysis and MD simulations of phytochemicals of3 Biotech · 2023
   Article
2. Targeting Akt/NF-κB/p53 Pathway and Apoptosis Inducing Potential of 1,2-Benzenedicarboxylic Acid, Bis (2-Methyl Propyl) Ester Isolated fromMolecules (Basel, Switzerland) · 2022
   Article
3. The Insulin Receptor: A Potential Target of Amarogentin Isolated fromBiomedicines · 2021
   Article
4. Ehretiquinone fromOxidative medicine and cellular longevity · 2021
   Article
5. Antioxidant Phytoconstituents FromFrontiers in pharmacology · 2020
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

4 authors.

Funding

Abstract

Indexed as